Beneficial Effect of Diazoxide in Obese Hyperinsulinemic Adults1
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Hyperinsulinemia, insulin resistance, and increased adipose tissue are hallmarks of the obesity state in both humans and experimental animals. The role of hyperinsulinemia as a possible preceding event in the development of obesity has been proposed. We previously demonstrated that administration of diazoxide (DZ), an inhibitor of insulin secretion, to obese hyperinsulinemic Zucker rats resulted in less weight gain, enhanced insulin sensitivity, and improved glucose tolerance. Assuming that hyperinsulinemia plays a major role in the development of human obesity, then its reversal should have therapeutic potential. To test this hypothesis, we conducted a randomized placebo-controlled trial in 24 hyperinsulinemic adults [body mass index (BMI) > 30 kg/m2]. All subjects were placed on a low-calorie (1260 for females and 1570 for males) Optifast (Sandoz, Minneapolis, MN) diet. After an initial 1-week lead-in period, 12 subjects (mean ± se for age and BMI, 31 ± 1 and 40 ± 2, respectively) received DZ (2 mg/kg BW·day; maximum, 200 mg/day, divided into 3 doses) for 8 weeks; and 12 subjects (mean± se for age and BMI, 28 ± 1 and 43 ± 1, respectively) received placebo. Compared with the placebo group, DZ subjects had greater weight loss (9.5 ± 0.69% vs. 4.6 ± 0.61%, P < 0.001), greater decrease in body fat (P < 0.01), greater increase in fat-free mass to body fat ratio (P < 0.01), and greater attenuation of acute insulin response to glucose (P < 0.01). However, there was no significant difference in insulin sensitivity and glucose effectiveness, as determined by the insulin-modified iv glucose tolerance test (Bergman’s minimal model) and no significant difference in glycohemoglobin values. Conclusion: 8 weeks treatment with DZ had a significant antiobesity effect in hyperinsulinemic obese adults without inducing hyperglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis
Bray, G. A., & York, D. A. (1979) · Physiological Reviews · doi:10.1152/physrev.1979.59.3.719 · Cited by 1,132
Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects.
Polonsky, K. S., Given, B. D., & Van Cauter, E. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113339 · Cited by 763 · cited 1×
“Polonsky et al. ( 15 ) demonstrated that temporal a pattern of insulin secretion in hyperinsulinemic obese adults was largely normal, which suggests that the functioning b-cell mass is enhanced but responds to normal regulatory mechanisms.”
BackgroundQuantitative study of insulin secretion and clearance in normal and obese subjects
Polonsky, K. S., Given, B. D., Hirsch, L., Shapiro, E. T., Tillil, H., Beebe, C., Galloway, J. A., Frank, B. H., Karrison, T., & Van Cauter, E. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113338 · Cited by 444
Cited by
Hyperinsulinemia Drives Diet-Induced Obesity Independently of Brain Insulin Production
Mehran, A. E., Templeman, N. M., Brigidi, G. S., Lim, G. E., Chu, K.-Y., Hu, X., Botezelli, J. D., Asadi, A., Hoffman, B. G., Kieffer, T. J., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.10.019 · Cited by 498
“Furthermore, blocking hyperinsulinemia with drugs including diazoxide or octreotide can cause weight loss in humans (Alemzadeh et al., 1998; Lustig et al., 2006), although interpretation of these studies is complicated by direct effects of these treatments on multiple tissues, including white fat (Shi et al.”
BackgroundCollins, S., Martin, T. L., Surwit, R. S., & Robidoux, J. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.02.006 · Cited by 485
Hyperinsulinemia in Obesity, Inflammation, and Cancer
Zhang, A. M. Y., Wellberg, E. A., Kopp, J. L., & Johnson, J. D. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0250 · Cited by 305
Weyer, C., Hanson, R. L., Tataranni, P. A., Bogardus, C., & Pratley, R. E. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2094 · Cited by 299
Janssen, J. A. M. J. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157797 · Cited by 294
Corkey, B. E. (2012) · Diabetes · doi:10.2337/db11-1483 · Cited by 285
The Role of Dairy Foods in Weight Management
Zemel, M. B. (2005) · Journal of the American College of Nutrition · doi:10.1080/07315724.2005.10719502 · Cited by 272
Fatty acid metabolism and insulin secretion in pancreatic beta cells
Yaney, G. C., & Corkey, B. E. (2003) · Diabetologia · doi:10.1007/s00125-003-1207-4 · Cited by 255
Hyperinsulinemia: A cause of obesity?
Erion, K. A., & Corkey, B. E. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0261-z · Cited by 161
Hamilton, J., Conwell, L., Syme, C., Ahmet, A., Jeffery, A., & Daneman, D. (2011) · International Journal of Pediatric Endocrinology · doi:10.1155/2011/417949 · Cited by 109
“It was well tolerated, without glucose intolerance [28].”
BackgroundMild suppression of hyperinsulinemia to treat obesity and insulin resistance
Page, M. M., & Johnson, J. D. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.03.018 · Cited by 99
Chaput, J.-P., Tremblay, A., Rimm, E. B., Bouchard, C., & Ludwig, D. S. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.2.303 · Cited by 73
Brauner, R., Serreau, R., Souberbielle, J.-C., Pouillot, M., Grouazel, S., Recasens, C., Zerah, M., Sainte-Rose, C., & Treluyer, J.-M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2126 · Cited by 37
“Sample size The sample size was determined on the basis of Alemzadeh et al (19), who reported in adults a mean SD weight loss after 8 weeks of 4.6 1% in a placebo arm.”
MethodInfluentialSuppression of insulin secretion in the treatment of obesity: a systematic review and meta-analysis
Huang, Z., Wang, W., Huang, L., Guo, L., & Chen, C. (2020) · Obesity · doi:10.1002/oby.22955 · Cited by 13
“Edema is one of the side effects in diazoxide treatment (28,33,36) and it can be resolved after 2 weeks of therapy (28).”
BackgroundResult
Metadata
- Authors
- Alemzadeh, R., Langley, G., Upchurch, L., Smith, P., & Slonim, A. E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1998-06-01
- Volume
- 83
- Issue
- 6
- Pages
- 1911-1915
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1972566455
- Cited by
- 112
- References
- 5
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.